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Abstract
In this paper we consider the design and analysis of studies comparing the pos-
itive and negative predictive values of two diagnostic tests that are measured on all
subjects. Although statistical methodology is well developed for comparing diagnostic
tests in terms of their sensitivities and specificities, comparative inference about pre-
dictive values is not. We derive analytic variance expressions for the relative predictive
values. Sample size formulas for study design ensue. In addition, two new methods
for analyzing the resulting data are presented and compared with an existing marginal
regression methodology.
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1 Introduction
Recent advances in biotechnology are leading to the development of many new medical tests.
Tests can be used for various purposes including diagnosis, prognosis, risk prediction, and
disease screening. In parallel, statistical methodology for evaluating these tests has received
much attention. Two recent books on the subject are references [1] and [2]. Various measures
can be used to quantify test accuracy. Frequently used measures for binary tests are the sen-
sitivity and specificity and the positive and negative predictive values. Let D = I{diseased}
denote an individual’s disease status and X = I{test positive} contain the results of a diag-
nostic test. Although we use terminology for diagnostic testing where the predicted outcome
is ‘presence of disease’, as noted above other binary outcomes, such as future occurrence of
an event, would be relevant for non-diagnostic tests. The sensitivity, P (X = 1|D = 1), and
the specificity, P (X = 0|D = 0), assess the probability of a correct test result conditional
on disease status. They determine the extent to which the test accurately reflects presence
or absence of disease and are often used in the early stages of test development [2, 3, 4].
On the other hand, the positive predictive value, PPV = P (D = 1|X = 1), and negative
predictive value, NPV = P (D = 0|X = 0), measure the probability of disease conditional
on the test result. They quantify the practical usefulness of the test for assessing disease
status. Predictive values are therefore important in the later stages of test development
when definitive studies of the test are conducted in large prospective cohorts.
Several authors have argued that the predictive values have greater clinical relevance than
sensitivity and specificity and are more directly applicable in patient care [5, 6]. Despite their
importance and practical relevance, statistical procedures for comparing predictive values is
3
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surprisingly limited, especially in comparison to methods for comparing sensitivities and
specificities.
Let X1 and X2 denote binary test results for two tests. In this paper we consider com-
parison of their positive predictive values, P (D = 1|X1 = 1) and P (D = 1|X2 = 1), and
comparison of their negative predictive values, P (D = 0|X1 = 0) and P (D = 0|X2 = 0).
Because the predictive values depend on the prevalence of disease, P (D = 1), naively es-
timating them from a study where P (D = 1|sampled) 6= P (D = 1) will result in biased
estimates. For this reason, we assume throughout that data are observed from a cohort
design where D, X1, and X2 are sampled jointly.
Data for comparing two tests often come from a paired study design. In contrast to an
unpaired design where each test is applied to a mutually exclusive group of individuals, in
a paired study both tests are assessed on all individuals. Pairing has the advantage that
it is statistically more efficient [2]. Moreover, applying both tests to the same individual
is intuitively appealing and eliminates confounding. Despite these advantages and the fact
that paired study designs are often used in practice, inference procedures for comparing
predictive values from such designs are not widely available.
Furthermore, we are not aware of any existing sample size calculations for paired designs
aimed at comparing the predictive values of two tests. Sample size calculations for comparing
predictive values from an unpaired design are available in the literature [2] and sample size
calculations for both unpaired and paired designs comparing sensitivity and specificity are
also available. (For summaries of these methods see references [1] and [2].) One aim of this
paper is to fill in this apparent gap to aid in the design of rigorous prospective cohort studies
necessary for definitive evaluation of medical tests.
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One promising method for comparing predictive values from a paired study design has
been described. Leisenring, Alonzo, and Pepe [7] propose a marginal regression framework
for analyzing such data. We review their approach below. In addition, we discuss two new
alternate approaches for formally comparing predictive values. The first involves a direct
computation of the relative predictive values and their standard errors and is also the basis
for the sample size calculations. It is not a regression approach, though, and as such does not
allow for adjustment of covariates that might affect the accuracy of the tests. The second
approach is a regression framework that uses only individuals for which the two test results
disagree (the discordant pairs).
This paper is organized as follows. In the next section we describe data from the National
Cystic Fibrosis Patient Registry which will be used to illustrate the methodology. Section 3
suggests metrics for comparing the predictive values, the relative predictive values. Variance
estimates for obtaining confidence intervals for the relative predictive values are detailed here
as well. In Section 4 we present sample size formulas derived using these variance expressions.
Section 5 describes the regression methodology suggested by Leisenring et al. while Section
6 contains a new regression framework for data analysis. In Section 7 we compare the three
different analysis methods in a simulation study. Conclusions are in Section 8.
2 National Cystic Fibrosis Patient Registry data
For illustrative purposes, the methodology developed in this paper will be applied to data
from the 1996 Cystic Fibrosis Foundation National Registry. We have previously analyzed
this data and describe it in greater detail in [8]. Briefly, patients with cystic fibrosis (CF) can
5
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have intermittent acute severe respiratory infections which are called pulmonary exacerba-
tions (PExs). While multiple studies have sought to assess the relationship between various
potentially predictive factors and PExs using a standard multivariate regression prognostic
factor analysis, few have attempted to compare factors in their ability to predict future PExs.
Consequently, here we compare two prognostic factors, (a) a positive culture for the bac-
terium Pseudomonas Aeruginosa in 1995 and (b) the occurrence of at least one PEx in 1995.
We explore using this information to predict subsequent PExs in 1996. Since CF patients
can have several PExs in a single year, we work with dichotomized variables indicating that
either a patient had no PExs in the relevant year or the patient had at least one PEx that
year. We have data available on 11,960 patients six years of age and older for this analysis.
Here the two “diagnostic tests” we wish to compare are actually risk factors. In this
context, presence of a risk factor is equated to testing positive. Further, these prognostic
factors are sought to predict a future event, not to diagnose a current condition. As noted
earlier, although the context differs from that of traditional diagnostic testing we see that
the statistical framework is the same.
3 Estimating the relative predictive values
Let Xj hold the result of test j, j = 1, 2. Its positive predictive value is PPVXj = P (D =
1|Xj = 1) and negative predictive value is NPVXj = P (D = 0|Xj = 0). There are a number
of ways to quantify differences in the predictive values. We focus here on relative predictive
values. The relative positive predictive value is defined as rPPV =
PPVX1
PPVX2
and the relative
negative predictive value is rNPV =
NPVX1
NPVX2
.
6
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Note that an ideal study will evaluate positive and negative predictive values together,
because taken separately they do not present a complete picture of the accuracy of the test.
Consider that it is possible to artificially inflate the PPV simply by declaring that everyone
has the disease regardless of the test result. While the PPV would be equal to one suggesting
a perfect test, the NPV would be zero correctly reflecting that the test is useless.
Data from a paired study can be summarized by the two tables shown in Table 1. There
the i = 1, ..., N individuals are classified into k = 1, ..., 8 cells. Corresponding to each of the
eight cells shown in the table, we assume that there is a true unobserved probability pk, where
∑8
k=1 pk = 1. In practice these probabilities are estimated by their empirical estimates,
nk
N
.
Thus PPVX1 =
p5+p6
p1+p2+p5+p6
is estimated by ̂PPV X1 = n5+n6n1+n2+n5+n6 , PPVX2 = p5+p7p1+p3+p5+p7 is
estimated by ̂PPV X2 = n5+n7n1+n3+n5+n7 , and similar expressions can be written for NPVX1 and
NPVX2 . The relative predictive values can be then estimated as
̂rPPV = P̂PV X1
P̂PV X2
=
(n5 + n6)(n1 + n3 + n5 + n7)
(n5 + n7)(n1 + n2 + n5 + n6)
(1)
̂rNPV = N̂PV X1
N̂PV X2
=
(n3 + n4)(n2 + n4 + n6 + n8)
(n2 + n4)(n3 + n4 + n7 + n8)
. (2)
Starting with the observation that the joint distribution of {D, X1, X2} is multinomial
with probabilities pk, we can apply the multivariate central limit theorem together with the
delta method to show that
1√
n
 log
̂rPPV − log rPPV
log ̂rNPV − log rNPV
 ∼ N

 0
0
 , Σ

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where
Σ =
 σ
2
P σPN
σPN σ
2
N
 .
The components of Σ are lengthy and complicated. This is particularly true of the covariance
σPN . To obtain simpler expressions for these variance components, we used the multinomial-
Poisson transformation which transforms the likelihood of the data into a Poisson likelihood
with additional parameters ([9]). We provide the resulting expressions in the appendix.
We can estimate the variance of log ̂rPPV and log ̂rNPV with σˆ2P
N
and
σˆ2
N
N
, respectively,
replacing each of the components in the expressions for σ2P and σ
2
N with their empirical
estimates. These estimates yield 100(1− α)% confidence intervals:
log ̂rPPV ± z1−α/2√ σˆ2PN (3)
log ̂rNPV ± z1−α/2√ σˆ2NN . (4)
By exponentiating (3) and (4) we obtain upper and lower confidence limits for ̂rPPV and
̂rNPV .
A 100(1 − α)% elliptical confidence region for (rPPV, rNPV ) is the set of (rPPV ,
rNPV ) such that
 log
̂rPPV − log rPPV
log ̂rNPV − log rNPV

T
∑̂
−1
 log
̂rPPV − log rPPV
log ̂rNPV − log rNPV
 ≤ χ22,α
where
∑̂
is the estimate of Σ.
In the CF data there are 5054 (42%) patients who had at least one PEx in 1996 (D = 1).
Further, 4972 patients had a PEx in 1995 (X1 = 1) and 308 patients were positive for
8
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P. Aeruginosa in 1995 (X2 = 1). Measuring the predictive accuracy of 1995 PEx, we
estimate PPV = 0.73 and NPV = 0.80. For P. Aeruginosa, we estimate PPV = 0.60 and
NPV = 0.58. We find rPPV = 1.22 and rNPV = 1.37. Separate 90% confidence intervals
for the rPPV and rNPV are (1.14, 1.34) and (1.35, 1.38) respectively. In contrast, Figure 1
shows the joint 90% confidence region for (rPPV , rNPV ). In both cases the rPPV and
rNPV are bounded well away from one indicating that 1995 PEx does a significantly better
job of predicting 1996 PEx.
4 Sample size formulas
The confidence intervals in (3) and (4) can be used to test hypotheses about the rPPV and
rNPV . Concentrating first on the rPPV , write the null hypothesis as H0(P ) : rPPV ≤ δ
where δ = 1 for a superiority study testing whether PPVX1 is larger than PPVX2. For a
non-inferiority study, to assess if PPVX1 is not substantially less than PPVX2 we take δ less
than but close to 1 . H0 is rejected if the lower confidence limit for rPPV is larger than
δ. Suppose we wish to design a study to have power 1− β under an alternative hypothesis
H1 : rPPV = γ. That is, we seek to choose the sample size so that with probability 1− β
the lower confidence limit for rPPV will exceed δ. Then
1− β = P
log ̂rPPV − z1−α
√
σ2P
N
> log δ | rPPV = γ
 (5)
Since
log ̂rPPV −log rPPV√
σ2
P
/N
∼ N(0, 1) and log rPPV = log γ under the alternative hypothesis,
we can rewrite (5) as
1− β = P
 log ̂rPPV√
σ2
P
N
>
log δ − log γ√
σ2
P
N
+ z1−α

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Solving for N we find
N =
(z1−α + z1−β)
2
(log (γ/δ))2
σ2P
We now need to insert a value for σ2P to calculate N . Under H1, PPVX1 = γPPVX2 yielding
σ2P =
2(p7 + p3)γPPV
2
X2 + (−p6 + p5(1− γ))PPVX2 + p6 + p7(1− 3γPPVX2)
(p5 + p6)(p5 + p7)
Thus the required sample size is
N =
(
(z1−α + z1−β)
log (γ/δ)
)2
× (6)
(
2(p7 + p3)γPPV
2
X2 + (−p6 + p5(1− γ))PPVX2 + p6 + p7(1− 3γPPVX2)
(p5 + p6)(p5 + p7)
)
For testing H0(N) : rNPV ≤ δ similar calculations result in the sample size formula
N =
(
(z1−α + z1−β)
2
log (γ/δ)
)2
× (7)
(−2(p4 + p8)γNPV 2X2 + (−p3 + p4 − γ(p2 − p4))NPVX2 + p2 + p3
(p2 + p4)(p3 + p4)
)
Both of these sample size formulas require specification not only of a predictive value
for the second test, a threshold value δ under the null hypothesis and an assumed value for
the rPPV under the alternative hypothesis, but of some additional probabilities as well.
Intuitively, the probabilities of test positivity, P (X1 = 1) and P (X2 = 1), and correlation
between the tests enter into the variances of ̂rPPV and ̂rNPV .
As an example, suppose we had two tests and were interested in testing whether the
positive predictive value of the first test was superior to the positive predictive value of the
second factor. We have previous data indicating that PPVX2 = 0.7 and wish to conclude
10
http://biostats.bepress.com/mskccbiostat/paper5
that the first test is superior if the rPPV = 1.2. Here δ = 1 and γ = 1.2. We estimate, from
prior data say, that p3 = 0.07, p5 = 0.2, p6=0, and p7 = 0.05. For significance level α = 0.05
with power=1− β = 0.90, we calculate from (6) that 192 subjects are needed.
We conducted a small simulation study to determine how well the formula given in (6)
worked in this example. Data was first simulated for 192 subjects under the null hypothesis,
rejecting H0 if the lower limit of the confidence interval for log rPPV was greater than 0,
and this process was repeated 1000 times. We then generated data under the alternative
hypothesis, fixing γ = 1.2, and repeated the same steps. (More details on how we generated
data can be found in Section 7.) Under both the null and alternative hypotheses, we explored
varying the number of positive test results for each test while holding the sample size and
PPV s fixed. In all situations we studied, the empirical size was always close to the nominal
0.05 level. As expected we found 90% power when the probabilities {p3, p5, p6, p7} were
chosen correctly (top row of Table 2). However the power was less in other scenarios. In
particular, when the number of subjects positive on both tests (N++) or on at least one test
(NP ) decreased, the power decreased.
If paired pilot data are available then such would be used to estimate the entries in Table 1
for substitution into the sample size formulas. Often, however, only data for studies of single
tests will be available, yielding tentative values for the marginal probabilities P (Xj = 1),
P (D = 1|Xj = 1), P (D = 1|Xj = 0), for j = 1, 2. Equivalently, these provide values for:
{p1+p2, p1+p3, p2+p4, p3+p4} and {p5+p6, p5+p7, p6+p8, p7+p8}. To complete the table
and hence the sample size calculations, some measures relating to the joint distribution of the
two tests need to be stipulated. For example P (X1 = 1, X2 = 1|D = 0) = p1/(p1+p2+p3+p4)
and P (X1 = 1, X2 = 1|D = 1) = p5/(p5 + p6 + p7 + p8) would suffice. A small paired case-
11
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control pilot study could yield estimates of these parameters.
5 Marginal regression models
As seen in Section 3, the relative positive and negative predictive values can be estimated
directly from the data. Leisenring, Alonzo, and Pepe (2000) take a different approach using
generalized linear models to compare predictive values. They reorganize their data into
long form, which is to say that each subject has two data records, one record for each test.
They define an indicator variable Z = I{Test 1} denoting to which test the record belongs.
Thus, a subject with data {D, X1, X2} has two records, {D, X, Z = 1} with X = X1 and
{D, X, Z = 0} with X = X2. They propose the positive predictive value model
g(P [D = 1|Z, X = 1]) = αP + βP Z (8)
and negative predictive value model
g(P [D = 1|Z, X = 0]) = αN + βNZ. (9)
Records with positive test results, i.e. for which X = 1, are used to fit model (8). Since
PPVX1 = P (D = 1|Z = 1, X = 1) and PPVX2 = P (D = 1|Z = 0, X = 1), model (8)
compares PPVX1 and PPVX2 with βP quantifying the difference between them on the g
scale. In contrast, by conditioning on records with negative test results, model (9) compares
NPVX1 and NPVX2 with βN quantifying the difference between them. The models can be
fit separately or simultaneously using GEE. Note that subjects can contribute none, one, or
two records to fitting the predictive value model. For example, if a subject tests positive on
12
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both tests, he will contribute two observations to fitting model (8), while if he tests positive
on only test 1 he will contribute only one record.
The interpretation of the βs depends upon the choice of the link function, g. Using the
logit link function as Leisenring et al. do, makes comparisons in terms of the odds ratios of
the predictive values. Then eβP is the ratio of the odds of disease given a positive result for
the first test compared to the odds of disease given a positive result for the second test. If
instead we use the natural logarithm as the link function, eβP is the relative positive predictive
value. Although both scales of comparison are valid, our focus is on the relative predictive
values in part because we feel they are more easily interpreted than odds ratios. Note also
that the estimates of the rPPV and rNPV obtained from these models are identical to
the estimates obtained using the formulas in Section 3. The standard error estimates can
differ between the two methods, at least in finite samples. We discuss and explore this point
further in Section 7.
These are marginal models, although not in the usual sense. The more familiar marginal
models developed by Liang and Zeger (1986) [10] are appropriate in the situation where there
are paired or multiple outcomes. In working with the predictive values, however, there is a
single outcome, D, while the diagnostic tests, X1 and X2, are paired. A naive application of
the Liang and Zeger marginal models to this data would involve modeling P (Xj|D). Notice
that this approach reverses the roles of the tests and D. It yields models appropriate for the
sensitivity and specificity, but not for the predictive values. Using D as the outcome, the
standard multivariate regression analysis would model P (D|X1, X2). This approach does
not allow direct comparison of P (D|X1) and P (D|X2). The models proposed by Leisenring
et al. are instead marginal with respect to the covariate, facilitating comparison of these two
13
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quantities by using the tests as covariates.
Fitting models (8) and (9) to the CF data using a log link function, we estimate the
rPPV comparing 1995 PEx to P. Aeruginosa is 1.22 with a 90% confidence interval of
(1.15, 1.34). We estimate the rNPV to be 1.37 with a 90% confidence interval of (1.35,
1.38). The estimates of the rPPV and the rNPV are the same as those presented in
Section 3, as we expected. Also notice that the confidence intervals obtained here using the
marginal regression approach differ only sightly from the confidence intervals obtained using
the analytic variance estimates derived above. Testing for differences using the generalized
score statistics described by Leisenring et al. indicates that both the PPV and NPV of
1995 PEx are significantly higher than the PPV and NPV of P. Aeruginosa with p < 0.001
in both cases.
6 Regression models using discordant pairs
McNemar’s test is a standard way of analyzing paired (or matched) binary data. It is used
to compare the sensitivities and specificities of two binary tests. McNemar’s test is based on
the idea that concordant pairs, pairs where both tests yield the same result (or where both
subjects have the same exposure in a matched case-control study) contain no information,
while discordant pairs, pairs where the two diagnostic tests yield different results, contain all
the vital information. The test statistic uses only the discordant pairs. McNemar’s test is
not directly applicable to compare the predictive values of two tests, because the predictive
values condition on the test result rather than disease status. The basic idea of using the
discordant pairs, however, is a natural way of analyzing paired binary data. Here we explore
14
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this idea and develop a new test statistic for comparing the predictive values based in a
regression framework.
For discordant pairs we define a new variable W
W =

0 if X1 = 1 and X2 = 0
1 if X1 = 0 and X2 = 1
Using W , the model
g(P [D = 1 | W, X1 6= X2]) = γ0 + γ1W
provides a regression framework for testing for differences between the two tests. If the
natural logarithm is used as the link function, eγ1 = P (D=1|X1=0,X2=1)
P (D=1|X1=1,X2=0)
is the ratio of the
probability of disease given a negative result on the first test and positive result on the
second test to the probability of disease given a positive result on the first test and a negative
result on the second. In general, a hypothesis test based on this model answers a different
question than the one in which we are primarily interested. That is, we are interested in
testing H0(P ) : P (D = 1|X1 = 1) = P (D = 1|X2 = 1) (and similarly H0(N)), but this new
approach tests the null hypothesis that HD : γ1 = 0, i.e. HD : P (D = 1|X1 = 1 and X2 = 0)
= P (D = 1|X1 = 0 and X2 = 1). Interestingly, however, we can show that when the
marginal probabilities of the two tests are equal, when P (X1 = 1) = P (X2 = 1), testing HD
is equivalent to testing H0(P ) and H0(N). See the proof in Appendix B. Moreover, we can
show that H0(P ) and H0(N) are equivalent so there is only one hypothesis to test. (This proof
is also included in Appendix B.)
Furthermore, when P (X1 = 1) = P (X2 = 1) the unstandardized score statistics for test-
ing the two hypotheses H0(P ) and HD are also equivalent. To see this, let ndisc denote the
15
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number of discordant pairs and define W¯ = 1
ndisc
∑ndisc
i=1 Wi, mi = X1i + X2i = 0, 1, or 2, the
number of positive test results for the ith individual, Z¯ =
(∑N
i=1 I{mi > 0}X2i
)
/
(∑N
i=1 mi
)
,
the proportion of all positive test results contributed by X2, and D¯
(βP ) =
(∑N
i=1 miDi
)
/
(∑N
i=1 mi
)
.
The standardized score statistic for testing HD is
S(γ1) =
(ndisc∑
i=1
{Wi(Di − D¯)}
)2
D¯(1− D¯)
ndisc∑
i=1
{(Wi − W¯ )2}
.
and the generalized score statistic for H0(P ) derived by Leisenring et al., written in different
notation than presented in their paper, is
S(βP ) =
(∑N
i=1{I{mi > 0}Di(X2i −miZ¯)}
)2
∑N
i=1{I{mi > 0}(Di − D¯(βP ))2(X2i −miZ¯)2}
The unstandardized score statistic for testing H0(P ), i.e. the square root of the numerator
of S(βP ), is the sum of two components:
N∑
i=1
I{mi > 0}Di(X2i −miZ¯) =
N∑
i=1
I{mi = 1}Di(X2i − Z¯) +
N∑
i=1
I{mi = 2}Di(1− 2Z¯) (10)
where we have simply broken I{mi > 0} into the two possibilities I{mi = 1} and I{mi = 2}
and then substituted the respective values for mi into the formula. The first term contains
only those individuals who have a positive result for a single test, i.e. the discordant pairs.
The second term contains those individuals who have positive results for both tests. To see
that this second term is equal to zero when the estimated marginal probabilities of the two
tests are equal, notice that in this situation Z¯ will always equal 0.5 because each test will
16
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contribute the same number of positive test results (Z¯ =
∑
X2i∑
X1i+X2i
). This result leaves only
the first term containing the discordant pairs. Further manipulation of this first term, which
we show in Appendix C, reveals that it can be rewritten as
∑ndisc
i=1 {Wi(Di − D¯)} which is
the unstandardized score statistic for testing HD. Thus, when the marginal probabilities of
the two factors are equal in a particular data application, the unstandardized score statistics
from the marginal GEE approach and the discordant pairs approach are exactly equal. Their
variances, however, are not.
Equation (10) implies that
var
(
n∑
i=1
I{mi > 0}Di(X2i −miZ¯)
)
=
var
(
n∑
i=1
I{mi = 1}Di(X2i − Z¯)
)
+ var
(
n∑
i=1
I{mi = 2}Di(1− 2Z¯)
)
+
2cov
(
n∑
i=1
I{mi = 1}Di(X2i − Z¯),
n∑
i=1
I{mi = 2}Di(1− 2Z¯)
)
(11)
In Appendix D we show that the covariance term is zero leaving only the first two terms
on the right side of (11). The implication of this result is that the variance of the score
statistic from the marginal GEE approach will always be at least as large as the variance
of the score statistic from the discordant pairs approach. Thus, S(γ1) is more efficient than
S(βP ) in this setting. Intuitively, when we use the discordant pairs score statistic to test
H0(P ) we assume that the marginal probabilities of the two diagnostic tests are equal and
hence variability in the second component of (10) is not at issue. Therefore, S(γ1) has a
narrower set of alternatives and is more powerful for these alternatives. Below we explore
this idea further in a simulation study.
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The gain in power when using this approach comes at the expense that it is only a valid
way for testing for differences in the positive and negative predictive values in the restricted
situations when P (X1 = 1) = P (X2 = 1). This situation, however, can occur fairly often in
practice. One example is when the two underlying tests are continuous and thresholds are
chosen so that the same percentage of people in the population test positive on both tests.
For instance, when comparing two screening tests that are inherently continuous in nature
(such as cancer biomarker levels), we may be willing to devote resources to further testing
on a certain percentage of individuals. This situation is not uncommon in a health policy
analysis framework. We can set the thresholds for positivity on the two tests to yield this
same percentage of “positive” individuals and compare the accuracy of the two tests using
this methodology. In Reference [8] we discuss analyzing the predictive values of continuous
diagnostic tests using this idea in more detail.
7 Simulation study
We conducted a simulation study to compare the three approaches described above. Simu-
lating data to have specified marginal distributions, P (D = 1|X1) and P (D = 1|X2), while
allowing each individual to have two binary tests but only a single outcome is not straight-
forward. We refer the interested reader to Leisenring et al. for more discussion of this point
as well as a detailed description of how data can be generated in this circumstance. We
simulated data in exactly the same way described there.
We had two aims in conducting this simulation study. Our first was to compare the
estimates of the variances of rPPV and rNPV using the expressions derived in Section 3 with
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those obtained from the regression approach of Leisenring et al. Although asymptotically
the variances are the same, there is the possibility that the estimates may differ in smaller
sample sizes.
For this purpose we fixed P (D = 1) = .2, PPVX2 = .7, NPVX2 = .9 and varied the
rPPV and rNPV . For some choices of PPVX1 and NPVX1 the simulated data resulted
in n1 + n2 = 0, n1 + n3 = 0, n6 + n8 = 0, or n7 + n8 = 0. While we could still calculate
the variance expressions in Σ for these situations, the GEE algorithm used to implement
Leisenring et al.’s approach failed to converge. In these situations we employed a small
sample correction, adding one observation to each cell of Table 1. We also slightly modified
the approach suggested by Leisenring et al. by creating a new variable D¯ = 1 − D and
modeling P (D¯|X = 0, Z) in order to estimate the rNPV .
Our second aim in this simulation study was to compare the properties of the score
statistic derived by Leisenring et al., S(βP ), with the score statistic based upon the discordant
pairs approach, S(γ1). For the reasons discussed in Section 6 we expected that using S(γ1)
would result in a more powerful test when the marginal distributions of the two tests are
the same. For this aim in addition to specifying parameters described in the preceding
paragraph, we also specified P (Xj = 1) and set P (X1 = 1) = P (X2 = 1).
Tables 3 and 4 show the results from the first aim. In general we found a very high degree
of correlation between the standard errors produced by the two methods with the analytic
expressions yielding slightly smaller estimates (Table 3). By comparing these standard errors
with the standard error from the simulated distribution of the statistic (column titled “Ac-
tual”) we see that for large sample sizes, both the analytic and GEE standard errors provide
equally good estimates of the standard errors. In the smaller sample sizes, both the analytic
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and GEE standard errors may over- or under-estimate the true standard error. For each
scenario considered, the direction of this difference is the same for both estimates with the
magnitude of the difference usually smaller for the estimates from the analytic expressions.
In addition, the coverage probabilities resulting from the two approaches are very close
(Table 4) . For the larger sample sizes, both approaches yield coverage probabilities close
to the nominal 90% level. For the smaller sample sizes, the coverage probabilities appear to
deviate from the nominal level. In some situations the coverage probabilities are too high
while in other situations they are too low. Generally the analytic variance expressions yield
coverage probabilities slightly closer to the nominal level than do the variance expressions
from GEE, but the difference is often minimal. Across all sample sizes, Tables 3 and 4
indicate that both variance estimates have similar properties. One does not appear to offer
any real advantage over the other.
The simulation results for our second aim are contained in Tables 5 and 6. We see that
the performance of the two statistics under the null hypothesis (Table 5) depends not so
much on the overall sample size, but on the number of subjects that are ultimately included
in the analysis denoted by NP and Ndisc. Observe that data for examining γ1 = 0 is always
a subset of that for examining βP = 0, Ndisc ≤ NP . For the larger sample sizes, both
statistics maintain the 0.05 level. As the sample size decreases, though, S(βP ) does a better
job of maintaining Type I error closer to the nominal rate.
As we expected, it appears that S(γ1) is the more powerful statistic (Table 6). Despite
the fact that it is based on a smaller effective sample size than is S(βP ), it still outperforms
S(βP ). We conclude that in a given application, if (i) one is relatively certain that the
marginal probabilities of the two factors are equal and (ii) numbers of discordant pairs are
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large enough for large sample distribution theory approximations to apply, basing a test for
equality of the two positive predictive values on the discordant pairs is preferable.
8 Discussion
In this paper we have developed two new ways of comparing the predictive values of two
tests that are assessed using a paired study design and compared them with a previously
proposed method by Leisenring et al. The first method involves directly estimating the
rPPV and rNPV and using analytic variance estimates. It results in estimates that are
the same as those of Leisenring et al. when a log link function g is used. The advantage
of our approach is that analytic variance expressions give rise to sample size formulas for
study design. For analysis, however, the marginal regression method has the advantage that
it can easily accommodate adjusting for covariates. When there are factors that might affect
the predictive accuracy of the two tests, we can include these factors and their interactions
terms with the tests in our model. In this way one can test whether the factors significantly
affect the predictive values of one or both of the tests and can estimate the predictive values
for different scenarios defined by these factors. Leisenring et al. discuss this point further in
their paper. A reasonable strategy in practice would be to design a study using our sample
size formulas but to use the regression framework for analysis.
The second method developed here is motivated by the standard way of analyzing paired
binary data and uses only the discordant pairs in the spirit of McNemar’s Test. This method
is easily implemented using simple widely available statistical procedures. In many situa-
tions, though, i.e. when P (X1 = 1) 6= P (X2 = 1), the hypothesis being tested in this
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method is different than the one in which we are interested. It does not directly pertain to
the predictive values nor is it entirely clear that the question that is being answered by this
approach is even relevant. In contrast, the direct approach and the approach of Leisenring et
al. provide general valid methods for comparing predictive values in a paired study design.
We have shown that when the marginal probabilities of a positive result on the two
diagnostic tests are equal, the discordant pairs approach does test for differences between
the predictive values and does so more efficiently. A disadvantage of the discordant pairs
approach, however, is that it cannot accommodate missing data; the values of both X1
and X2 must be known for a subject to be included in the analysis. In contrast, with
the other two approaches if the result of one diagnostic test is missing for a given subject,
information on their known test result can still be included in the analysis. These methods
fundamentally are based on estimation of the individual predictive values, the marginal
probabilities P (D = 1|Xj) j = 1, 2, which utilize information from only a single diagnostic
test (i.e. estimating PPVXj requires knowledge of only the result of the j
th test).
The biostatistical literature on test accuracy has focused on the diagnostic setting. But as
we have emphasized, testing is done more broadly. In the cystic fibrosis data, for example,
the purpose is prognostic, to predict occurrence of a future event. Predictive values are
ultimately most important for quantifying the practical usefulness of a test. Moreover,
statistical methodology is the same regardless of the application. However, the context
for application does play a role in considering how and why predictive values of two tests
may differ. In the diagnostic setting, where the purpose is to detect presence or absence
of a condition, predictive values may differ because the tests differ in their sensitivities and
specificities to the condition. In the prognostic context on the other hand, one thinks simply
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in terms of risk inferred by factors yielding a positive test result.
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Appendix A
σ2P =
1
(p5 + p7)(p5 + p6)
× {p6(1− PPVX2) + p5(PPVX2 − PPVX1) +
2(p7 + p3)PPVX1PPVX2 + p7(1− 3PPVX1)}
σ2N =
NPVX2(−p3 + p4 − 2(p4 + p8)NPVX1) + (p2 + p3)−NPVX1(p2 − p4)
(p2 + p4)(p3 + p4)
Appendix B
Here we show that when P (X1 = 1) = P (X2 = 1) testing HD is equivalent to testing H0(P )
and H0(N). That H0(P ) and H0(N) are equivalent in this situation can be seen by
P (D = 1|X1 = 1) = P (D = 1|X2 = 1)
⇒ P (D = 0|X1 = 1) = P (D = 0|X2 = 1)
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⇒ P (D = 0)− P (D = 0, X1 = 0)
P (X1 = 1)
=
P (D = 0)− P (D = 0, X2 = 0)
P (X2 = 1)
⇒ P (D = 0|X1 = 0)P (X1 = 0)
P (X1 = 1)
=
P (D = 0|X2 = 0)P (X2 = 0)
P (X2 = 1)
⇒ P (D = 0|X1 = 0) = P (D = 0|X2 = 0).
Proof of the equivalence of HD and H0(P ) is simplified by noticing that P (X2 = 1|X1 =
1) = P (X1 = 1|X2 = 1) if and only if P (X1 = 1) = P (X2 = 1). To verify this statement
begin by supposing that P (X2 = 1|X1 = 1) = P (X1 = 1|X2 = 1). Then P (X1 = 1, X2 =
1)/P (X1 = 1) = P (X1 = 1, X2 = 1)/P (X2 = 1) implying that P (X1 = 1) = P (X2 = 1).
If instead we begin by supposing that P (X1 = 1) = P (X2 = 1), then P (X1 = 1, X2 =
1)/P (X1 = 1) = P (X1 = 1, X2 = 1)/P (X2 = 1) implying that P (X2 = 1|X1 = 1) =
P (X1 = 1|X2 = 1). Also notice that P (X2 = 1|X1 = 1) = P (X1 = 1|X2 = 1) implies that
P (X2 = 0|X1 = 1) = P (X1 = 0|X2 = 1).
To show the equivalence of HD and H0(P ) we write,
P (D = 1|X1 = 1) = (12)
P (D = 1|X1 = 1, X2 = 1)P (X2 = 1|X1 = 1) +
P (D = 1|X1 = 1, X2 = 0)P (X2 = 0|X1 = 1)
P (D = 1|X2 = 1) = (13)
P (D = 1|X1 = 1, X2 = 1)P (X1 = 1|X2 = 1) +
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P (D = 1|X1 = 0, X2 = 1)P (X1 = 0|X2 = 1)
The first probability, P (D = 1|X1 = 1, X2 = 1), on the right side of the equation is
the same in both (12) and (13). Given the equivalence of P (X2 = 1|X1 = 1) and P (X1 =
1|X2 = 1) and of P (X2 = 0|X1 = 1) and P (X1 = 0|X2 = 1), if HD is true it must also be
that H0(P ) is true. Conversely, if H0(P ) is true it must also be that HD is true.
Appendix C
To see that the first term on the right hand side of equation (10) is equivalent to the
unstandardized score statistics for testing HD when P (X1 = 1) = P (X2 = 1), first note that
Z¯ = .5 =
∑ndisc
i=1
wi
ndisc
since
∑ndisc
i=1
wi
ndisc
is just the fraction of positive results for X2 among all
discordant test results. This equality allows us to write
n∑
i=1
{I{mi > 0}Di(X2i −miZ¯)}
=
ndisc∑
i=1
{Di(X2i − Z¯)}
=
ndisc∑
i=1
DiX2i −
ndisc∑
i=1
DiZ¯
=
ndisc∑
i=1
Diwi −
(
ndisc∑
i=1
Di
)(∑ndisc
i=1 wi
ndisc
)
=
ndisc∑
i=1
Diwi −
(∑ndisc
i=1 Di
ndisc
)(
ndisc∑
i=1
wi
)
=
ndisc∑
i=1
{wi(Di − D¯)}
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which is the unstandardized score statistic from the discordant pairs approach.
Appendix D
In this Appendix we show that the covariance term in (11) is zero. This task is greatly
simplified by first proving that the expected value of the second term in (10) is zero when
we assume that P (X1 = 1) = P (X2 = 1).
Assume that P (X1 = 1) = P (X2 = 1). Then
n∑
i=1
E
[
I{mi = 2}Di(1− 2Z¯)
]
= 0
Proof
n∑
i=1
E
[
I{mi = 2}Di(1− 2Z¯)
]
=
n∑
i=1
{
P (mi = 2) E
[
I{mi = 2}Di(1− 2Z¯) | mi = 2
]
+
P (mi 6= 2) E
[
I{mi = 2}Di(1− 2Z¯) | mi 6= 2
]}
=
n∑
i=1
P (mi = 2) E
[
Di(1− 2Z¯) | mi = 2
]
+ 0
=
n∑
i=1
P (mi = 2) E
[
(1− 2Z¯) E(Di | Z¯, mi = 2) | mi = 2
]
=
n∑
i=1
P (mi = 2) P (D | mi = 2) E
[
(1− 2Z¯) | mi = 2
]
=
n∑
i=1
P (mi = 2) P (D | mi = 2)× 0
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The next to last equality follows by assuming that P (X1 = 1) = P (X2 = 1) once we know
that an individual is positive for both diagnostic tests (mi = 2), knowing the proportion of
all positive results that belong to the second test does not add any additional information
in determining and individual’s outcome, D. Hence, conditional on mi = 2, D and Z¯ are
independent. The last equality follows because Z¯ = .5 when P (X1 = 1) = P (X2 = 1).
This result seems rather intuitive when we think of the second term in (10) as the part of
the marginal regression score statistic that tests for a difference in the marginal probabilities
of the two diagnostic tests. The expected value of this term is zero under its particular
portion of the null hypothesis. Now we can easily show that the covariance term in (11) is
zero by writing
cov
(
n∑
i=1
I{mi = 1}Di(X2i − Z¯),
n∑
i=1
I{mi = 2}Di(1− 2Z¯)
)
=
n∑
i=1
cov
(
I{mi = 1}Di(X2i − Z¯), I{mi = 2}Di(1− 2Z¯)
)
=
n∑
i=1
{
E
[(
I{mi = 1}Di(X2i − Z¯)
) (
I{mi = 2}Di(1− 2Z¯)
)]
−
(
E
[
I{mi = 1}Di(X2i − Z¯)
]) (
E
[
I{mi = 2}Di(1− 2Z¯)
])}
An individual cannot have a positive result for exactly one factor and positive results for
both factors at the same time, so E
[(
I{mi = 1}Di(X2i − Z¯)
) (
I{mi = 2}Di(1− 2Z¯)
)]
= 0.
This fact together with the above claim shows that the covariance term is zero.
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Table 1: Data from a paired study design
D = 0
X2 = 1 X2 = 0
X1 = 1 n1 n2
X1 = 0 n3 n4
D = 1
X2 = 1 X2 = 0
X1 = 1 n5 n6
X1 = 0 n7 n8
Table 2: Empirical power for testing H0 : rPPV ≤ 1 with N = 192 and α = 0.05. PPVX2 =
.7 and γ = 1.2 are fixed across all simulations while the average number of subjects positive
on both tests, N++, and the average number of subjects positive on at least one test, NP ,
vary. Results shown are averages across 1000 simulations.
N++ NP Power
61 87 0.90
57 85 0.89
52 83 0.85
49 82 0.82
37 72 0.72
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1.1 1.2 1.3 1.4 1.5
1.
1
1.
2
1.
3
1.
4
1.
5
rPPV
rN
PV
Figure 1: Predicting 1996 pulmonary exacerbations: elliptical confidence region comparing
information on 1995 pulmonary exacerbations vs. a culture for P. Aeruginosa
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Table 3: Comparison of the estimated standard errors of log ̂rPPV from the analytic variance
expressions in Appendix A and the Leisenring et al. GEE approach. Results are based on
1000 simulations with P (D = 1) = .2, PPVX2 = .7, and NPVX2 = .9.
Standard Error†
N rPPV PPVX1 rNPV NPVX1 P (X1 = 1) P (X2 = 1) Analytic GEE Actual
500 1.1 .77 1.0 .90 0.15 0.17 .0770 .0773 .0712
1.1 .77 1.1 .99 0.25 0.17 .0696 .0699 .0692
1.2 .84 1.0 .90 0.14 0.17 .0750 .0754 .0743
1.2 .84 1.1 .99 0.23 0.17 .0690 .0693 .0703
100 1.1 .77 1.0 .90 0.15 0.17 .1806 .1851 .1802
1.1 .77 1.1 .99 0.25 0.17 .1604 .1635 .1596
1.2 .84 1.0 .90 0.14 0.17 .1764 .1810 .1724
1.2 .84 1.1 .99 0.23 0.17 .1592 .1624 .1647
50 1.1 .77 1.0 .90 0.15 0.17 .2604 .2791 .2355
1.1 .77 1.1 .99 0.25 0.17 .2034 .2094 .1579
1.2 .84 1.0 .90 0.14 0.17 .2276 .2356 .1749
1.2 .84 1.1 .99 0.23 0.17 .2053 .2111 .1662
† Presented is the average across simulations of the standard error estimates obtained from first the analytic
variance and then the GEE approach, and the actual standard error of log ̂rPPV across the simulations.
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Table 4: Comparison of the coverage probabilities for 90% confidence intervals obtained
by using the variance estimates in Appendix A with those estimates obtained from the
Leisenring et al. marginal GEE approach. Results are based on 1000 simulations with
P (D = 1) = .2, PPVX2 = .7, and NPVX2 = .9.
rPPV rNPV (Correct†)
N rPPV PPVX1 rNPV NPVX1 Analytic GEE Analytic GEE
500 1.1 .77 1.0 .90 89.3 89.7 90.2 90.9 (.00)
1.1 .77 1.1 .99 89.8 90.0 90.0 90.0 (.02)
1.2 .84 1.0 .90 90.9 91.0 89.5 89.4 (.00)
1.2 .84 1.1 .99 89.4 89.5 90.1 90.1 (.02)
100 1.1 .77 1.0 .90 92.3 92.8 89.2 89.3 (.07)
1.1 .77 1.1 .99 91.4 91.9 88.3 88.3 (.47)
1.2 .84 1.0 .90 89.7 90.7 90.3 90.3 (.11)
1.2 .84 1.1 .99 90.3 90.5 87.1 87.5 (.49)
50 1.1 .77 1.0 .90 93.1 93.8 90.1 91.6 (.43)
1.1 .77 1.1 .99 96.8 96.9 89.4 89.7 (.73)
1.2 .84 1.0 .90 95.2 95.9 94.2 94.5 (.40)
1.2 .84 1.1 .99 95.3 96.0 89.4 89.6 (.76)
† Fraction of the simulations in which a small sample correction was made.
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Table 5: Comparison of the empirical size of the score statistic, S(βP ), derived by Leisenring
et al., and the score statistic from the discordant pairs approach, S(γ1). Results are based
on 1000 simulations with P (D = 1) = .2.
N P (Xj = 1) PPVXj PDV1,0
a PDV0,1
b NP
c Ndisc
d P (S(·) > χ21,.95)
S(βP ) S(γ1)
500 .1 .8 .66 .66 75 48 .0420 .0460
.2 .8 .42 .42 126 53 .0420 .0460
.3 .6 .16 .15 193 87 .0460 .0550
100 .1 .8 .67 .67 15 10 .0920 .0940
.2 .8 .42 .41 25 11 .0620 .0750
.3 .6 .15 .16 39 17 .0610 .1180
50 .1 .8 .66 .65 7 5 .2110 .3400
.2 .8 .43 .40 13 5 .0830 .2710
.3 .6 .16 .16 19 9 .0560 .2830
a Average PDV0,1 = P (D = 1|X1 = 1, X2 = 0) across the simulations.
b Average PDV1,0 = P (D = 1|X1 = 0, X2 = 1) across the simulations.
c Average number of subjects with at least one positive test result.
d Average number of subjects with discordant test results.
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Table 6: Comparison of the empirical power of the score statistic, S(βP ), derived by Leisen-
ring et al., and the score statistic from the discordant pairs approach, S(γ1). Results are
based on 1000 simulations with P (D = 1) = .2.
N P (Xj = 1) PPVX1 PPVX2 PDV
a
1,0 PDV
b
0,1 N
c
P N
d
disc P (S(·) > χ21,.95)
S(βP ) S(γ1)
500 .1 .8 .5 .78 .28 80 60 .9660 .9750
.2 .8 .5 .76 .10 145 90 1.0000 1.0000
.2 .8 .7 .58 .27 132 64 .5540 .7090
100 .1 .8 .5 .77 .28 16 12 .3580 .4040
.2 .8 .5 .75 .10 29 18 .7600 .8400
.2 .8 .7 .56 .27 27 13 .1460 .1920
50 .1 .8 .5 .78 .28 8 6 .2270 .3610
.2 .8 .5 .77 .10 14 9 .4510 .5700
.2 .8 .7 .57 .29 13 6 .1330 .2270
a Average PDV0,1 = P (D = 1|X1 = 1, X2 = 0) across the simulations.
b Average PDV1,0 = P (D = 1|X1 = 0, X2 = 1) across the simulations.
c Average number of subjects with at least one positive test result.
d Average number of subjects with discordant test results.
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